Intec Pharma's net income is $-14M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2021
Trailing 12 months ending Mar 2021
Loading...
Loading...
Intec Pharma (NTEC) currently reports a net income of $-14M as of March 2021. That compares with $-41M in the prior-year period — up 64.5% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Intec Pharma's net income history and peer comparisons.
Intec Pharma's net income increased from $-41M to $-14M — a 64.5% year-over-year increase (period ending March 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Intec Pharma's net income of $-14M is lower than the Healthcare sector average of $16B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Intec Pharma reported $-14M in net income as of March 2021. That compares with $-41M in the prior-year period — up 64.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-14M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Intec Pharma, and consider following NTEC for alerts when major investors trade the stock.